ACRES Commercial Realty Corp. — News

Favorable, differentiated safety profile and durable single-agent clinical activity, including in heavily pretreated subjects with lung cancer remaining on treatment for over a year Oral weekly regimen (3 days on/4 days off) at 120 mg and 160 mg QD dose levels selected for randomized dose optimization across AP3-informed solid tumor populations Dose expansion to evaluate biomarker-selected small cell lung cancer (SCLC), squamous non-small cell lung cancer (sqNSCLC), lung adenocarcinoma (adNSCLC), as well as endometrial, cervical, and esophago-gastric junction cancers WATERTOWN, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 (Acrivon Predictive Precision Proteomics) platform deployed for rational drug design and predictive clinical development, today announced that ACR-2316 has advanced into the randomized dose expansion portion of its ongoing Phase 1/2 study.

globenewswire.com - 2026-08-05 08:30:00

ACRES Commercial Realty Corp. posted a disappointing Q2 2026, with book value dropping 10% to $26.76/share. Management internalization drove significant one-time costs, with $4.9M in equity compensation and $5.1M in merger expenses impacting net income. The capital structure is unusually preferred-heavy, with $224M in preferred equity versus $189M in common, raising concerns for preferred holders.

seekingalpha.com - 2026-07-31 03:04:49

ACRES Commercial Realty Corp. (ACR) Q2 2026 Earnings Call Transcript

seekingalpha.com - 2026-07-30 17:13:23

ACRES Commercial (ACR) came out with a quarterly loss of $0.74 per share versus the Zacks Consensus Estimate of $0.11. This compares to earnings of $0.04 per share a year ago.

zacks.com - 2026-07-29 19:26:46

UNIONDALE, N.Y., July 29, 2026 /PRNewswire/ -- ACRES Commercial Realty Corp.

prnewswire.com - 2026-07-29 16:11:00

Investors need to pay close attention to ACR stock based on the movements in the options market lately.

zacks.com - 2026-07-23 09:36:05

ACR, AEM and AYTU have been added to the Zacks Rank #5 (Strong Sell) List on July 20, 2026.

zacks.com - 2026-07-20 07:36:09

UNIONDALE, N.Y., July 15, 2026 /PRNewswire/ -- ACRES Commercial Realty Corp. (NYSE: ACR) (the "Company") announced today that it will release its results for the second quarter 2026, on Wednesday, July 29, 2026, after the market closes.

prnewswire.com - 2026-07-15 16:12:00

Acrivon Therapeutics (ACRV) trades below cash value, with the market deeply discounting its platform and pipeline despite promising early data. ACRV's AP3 platform enables precision patient-matching for kinase inhibitor therapies, showing a 50% response rate in serous endometrial cancer with ACR-368. Key near-term catalysts include Phase 2b ACR-368 data and Phase 1 ACR-2316 expansion results, both critical for de-risking and expanding commercial potential.

seekingalpha.com - 2026-07-13 04:44:48

GE HealthCare will showcase its latest enterprise imaging solutions at the Society for Imaging Informatics in Medicine (SIIM) 2026 Annual Meeting in Pittsburgh

gurufocus.com - 2026-06-09 10:00:00

UNIONDALE, N.Y., May 27, 2026 /PRNewswire/ -- ACRES Commercial Realty Corp. (NYSE: ACR) (the "Company") announced today that its Board of Directors declared cash dividends on its Preferred Stock.

prnewswire.com - 2026-05-27 16:15:00

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws

prnewswire.com - 2026-05-12 02:56:00

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the merger of ACRES Commercial Realty Corp. (NYSE: ACR) ("ACR" or the "Company") and ACRES Capital Corp. ("ACC") pursuant to which ACR will acquire ACC in an all-stock transaction. Under the terms of the proposed transaction, upon closing of the Merger, the Company will issue approximately 7.5 million shares of ACR'.

businesswire.com - 2026-05-06 11:56:00